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ABSTRACT
SAFETY AND IMMUNOGENICITY OF THE NATURAL LECTIN GRIFFFITHSIN
IN MICE
Amanda Lasnik
July 31, 2013

Griffithsin (GRFT) is a protein derived from the red alga Griffithsia sp. off
the coast of New Zealand. It binds and inactivates number of enveloped viruses
including HIV-1. For a product to be developed as a microbicide, it must be safe
and effective after repeated use. For initial in vivo safety testing we exposed
mice repeatedly to various vaginal products and found that increased
concentration of mouse serum albumin (MSA) in the vaginal lumen is predictive
of epithelial damage. Repeated intravaginal administration of GRFT did not
result in increased amounts of MSA, but the known epithelial disrupters
nonoxynol-9 and benzylkonium chloride caused increased concentrations of
MSA that were detectable by ELISA and western blot. We also evaluated the
immunogenicity of GRFT following repeated exposure and found that intravaginal
administration resulted in higher serum IgG antibody titers, but not local IgA or
IgG levels, than did subcutaneous administration. The consequences of the
systemic immune response are unknown and require further investigation.
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CHAPTER 1

INTRODUCTION

HIV Biology
Human Immunodeficiency Virus type 1 (HIV-1) is the causative agent of
acquired immunodeficiency syndrome (AIDS). It is in the lentivirus family of
retroviruses. The genome consists of two copies of single-stranded RNA
comprising nine open reading frames which encode 15 proteins. The gag gene
encodes a polyprotein which is further processed into the viral structural proteins
including the matrix (p17), capsid (p24) and nucleocapsid (p6 and p7) proteins.
The enzymes required for the viral life cycle - reverse transcriptase, protease,
and integrase - are encoded by the pol gene. The env gene codes for the
precursor glycoprotein gp160 which is processed to give rise to the viral
envelope glycoproteins gp120 and gp41. The regulatory genes tat and rev and
the accessory genes nef, vpu, vif, and vpr encode their eponymous proteins.
The gp120/gp41 spike plays an important role in attachment and entry of
the virus to the host cell, and is therefore a major focus of current research. The
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precursor protein gp160 is synthesized in the endoplasmic reticulum, where it
oligomerizes to form a trimer. The trimer is transported through the trans-Golgi
network, where it is glycosylated primarily with high-mannose glycans and
cleaved by furin to produce the surface (gp120) and transmembrane (gp41)
glycoproteins. These glycoproteins associate with each other in a non-covalent
manner. The initial step in HIV infection is the association of gp120 with the host
cell’s CD4 receptor. This step is followed by interaction of gp120 with the
chemokine co-receptor CCR5 or CXCR4. CCR5 is the major co-receptor initially
associated with sexually transmitted HIV; advanced AIDS is marked by a shift in
the preferential binding of gp120 to CXCR4. The interaction of gp120 and the
co-receptor results in a conformational change which exposes gp41. This
mediates fusion of the virus to the cell membrane and results in viral entry. The
entry process is outlined in Figure 1-1.

Figure 1-1. The three main steps in HIV entry into the cell.
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Prevention of HIV by Microbicides
There are currently 33.3 million people infected with HIV-1, with 2.6 million
new infections each year (UNAIDS Global Report, 2010). A vaccine to prevent
HIV-1 infection remains a priority for researchers, but developing a vaccine
against this virus is complicated by a number of factors. HIV-1 exhibits
tremendous genetic diversity due to its error-prone reverse transcriptase which
introduces approximately 1 error for every round of replication. This makes it
difficult for the immune system to target the virus effectively. Additionally, HIV-1
targets the immune system, which compromises the host’s ability to adequately
fight infection. HIV-1 inserts copies of its reverse-transcribed DNA into cells,
creating a reservoir of the virus and thus necessitating life-long treatment with
drugs that will keep the HIV viral load low. While a clinical trial demonstrated
moderate success (31% efficacy) for a vaccine, further research is necessary [1].
Until an efficacious vaccine is developed, other methods of prevention are
required.
Women are more likely to contract HIV from an infected heterosexual
partner than vice versa, especially in regions of high HIV incidence. Current
strategies for risk reduction – abstinence, monogamy, and consistent condom
use – are often not feasible for women to negotiate, and male circumcision does
not protect women from HIV. Additionally, products which prevent sexually
transmitted infections but maintain fertility are of particular interest. Therefore a
woman-controlled alternative to the male condom must be considered to slow the
spread of HIV.
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Microbicides are products that can be applied vaginally or rectally prior to
sexual intercourse to prevent the transmission of HIV-1 or other sexually
transmitted infections. They may be broadly classified in one of three categories:
(1.) non-specific HIV inhibitors; (2.) agents that prevent viral replication; and (3.)
entry inhibitors that prevent binding of the virus to cellular receptors. Early efforts
in the microbicide field used products that had non-specific mechanisms of action
against HIV. Though in vitro assays showed promise, clinical trials with the
spermicidal detergent Nonoxynol-9 (N-9) demonstrated an increase in the risk of
infection with repeated use [2,3,4]. C31G (Savvy) also showed good in vitro
bactericidal and virucidal properties; however two large clinical trials were halted
due to lower than expected seroconversion rates in both arms of the trial
population. Additional data analysis indicated a non-significant trend towards
harm in the C31G users compared to the placebo group [5]. Acidifying agents
that lower the vaginal pH and inactivate HIV and other pH-sensitive pathogens
comprise another group of non-specific HIV inhibitors. Although these agents
are inexpensive and readily available, clinical studies proved them to be
ineffective [6].

Table 1-1 outlines some of the clinical trials to date. A

comprehensive systematic review and meta-analysis all major clinical trials can
be found in [7].
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Product

Category

Clinical trial outcomes

Ref.

Cellulose Sulfate
/ Ushercell

Non-specific inhibitor
(anionic polymer)

Two Phase III studies halted due to
increased HIV incidence in one study

[8]

Pro 2000

Non-specific inhibitor
(anionic polymer)

Phase III trial completed
Product showed safety but not efficacy

[9]

BufferGel

Non-specific inhibitor
(acidifier)

Phase II trial completed
Initial results indicate it is not efficacious

[10]

N-9

Non-specific inhibitor
(detergent)

Phase III trials completed
Increased HIV incidence in experimental
group

[2,3,4]

Carraguard

Non-specific inhibitor
(anionic polymer)

Phase III trial completed
Product showed safety but not efficacy

[11]

C31G / Savvy

Non-specific inhibitor
(detergent)

Phase III study halted due to low HIV
incidence in study population

[5]

Tenofovir

Viral replication
inhibitor

Phase II trial completed
39% overall reduction in new HIV infections

[12]

Table 1-1. Selected microbicide clinical trial outcomes.

Agents that prevent viral replication represent a second class of
microbicides. In June 2010 a report outlined the success of the CAPRISA 004
Phase II trial employing a gel formulation of 1% tenofovir, a nucleotide reverse
transcriptase inhibitor [12]. The study showed an overall reduction in HIV
acquisition of 39% and a reduction of 54% for those with high protocol
adherence. Surprisingly, 1% tenofovir gel also protected against herpes simplex
virus type 2 (HSV-2) infection, with an efficacy of 51% in this study (reviewed in
[13]). HSV-2 is a well-established co-factor for HIV transmission and therefore
the results of this study were encouraging. However a larger follow-up study
(VOICE trial) showed no efficacy whatsoever and was halted due to futility. The
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CAPRISA 004 trial used a protocol in which women were instructed to use the
gel within 12 hours before sexual intercourse and again within 12 hours after
sexual activity, while daily administration was used in the VOICE study. It’s
unknown whether a difference in protocol or a difference in adherence between
the two trials resulted in disparate results, and further studies are pending. There
are additional safety concerns regarding the use of antiretroviral drugs for
prevention. In an earlier clinical trial, systemic absorption was detected in a
majority of participants [14]. Absorption of low levels of this effective drug may
select for viral resistance in those already infected, and further studies are
required. Because of the highly mutable nature of HIV, microbicidal products will
likely be formulated as a combination of two or more drugs with different
mechanisms of action, such as tenofovir combined with an entry inhibitor. .
Agents that interfere with the interaction between HIV and the host may be
further classified into two groups: those that bind to the virus, and those that bind
to the receptors. Compounds that target cellular receptors are attractive
candidates because they presumably will not cause escape mutants; however
care must be taken to ensure that these agents do not interfere with receptor
function. Agents in this class of compounds include monoclonal antibodies
against CD4, CCR5 inhibitors, analogs of the chemokine RANTES, and inhibitors
of C-type lectins such as DC-SIGN. The monoclonal antibody ibalizumab is
specific for CD4 and prevents interaction with HIV, but does not block MHC class
II molecules [15]. It is currently in clinical trials as an injectable therapeutic, but
could be developed as a topical agent. Since CCR5 is the primary co-receptor
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for sexually transmitted HIV-1 and predominates during early stages of infection,
compounds that sequester or block CCR5 at the mucosal surface may provide
protection. However it remains to be seen if blocking CCR5 will result in an
increase in infection caused by viruses that use CXCR4 to gain entry. Synthetic
analogs of the chemokine RANTES, such as PSC-RANTES, also inhibit CCR5.
PSC-RANTES provided complete protection against SHIV SF162 in macaques,
although the dose required was relatively high at 1 mM [16]. Finally, several
studies have implicated C-type lectins, especially DC-SIGN, as a major
mechanism by which HIV is trapped by antigen presenting cells and presented to
CD4+ cells [17,18,19]. Mannan, a mannose-rich oligosaccharide derived from
yeast, was able to block DC uptake of HIV in vitro, but was ineffective in
preventing HIV transmission in a macaque challenge with SHIV [20].
Compounds that bind to the HIV envelope and prevent cellular attachment
are especially promising. The CD4-binding pocket of the viral envelope protein
gp120 is highly conserved and small molecules or monoclonal antibodies that
target this region are potential candidates. The broadly neutralizing human
monoclonal antibody 2G12 is specific for the glycans on gp120. While it showed
promise in early clinical trials in a cohort of patients infected with HIV-1, it also
resulted in escape mutants in a majority of these participants [21,22]. Another
target is the cellular fusion of the virion, which is mediated by the gp41 trimer.
Enfuviritide is a synthetic peptide that binds gp41 and prevents viral fusion.
Unfortunately, this peptide readily causes escape mutants when administered to
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patients with HIV [23]; it is unknown if selection of mutants would be enhanced
by topical administration.
While monoclonal antibodies and other recombinant proteins may provide
good protection against HIV, the cost to produce them at a large scale could be
prohibitively expensive. We recently described the production of an HIV
microbicide, Griffithsin (GRFT), via a plant-based expression system employing a
recombinant viral vector [24]. Because the upstream costs of plant manufacture
are lower than traditional “closed” cell culture systems, the cost to manufacture
GRFT per dose is similar to that of the male condom, a practical requirement for
the use of microbicides.

Antiviral lectins as candidate microbicides

Many viruses, including HIV-1, are heavily glycosylated. The HIV-1
envelope protein gp120 is more than 50% glycan by mass. Approximately 40%
of the N-linked glycosylation sites are occupied by the high-mannose type
glycans, with the remainder of the sites occupied by complex-type glycans. HIV
uses this glycan shield to evade the host immune system and also to facilitate
infection of T cells via C-type lectins, such as DC-SIGN, present on dendritic
cells. These glycans are attractive targets for HIV inhibition.
Many lectins are derived from natural sources such as plants,
cyanobacteria, and marine algae, and most of these have potent HIV inhibitory
activity. Several of these lectins are summarized in Table 2. GRFT, first
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described in 2005, is a 12,770 Da protein derived from the red alga Griffithsia sp.
off the coast of New Zealand [25]. It is the most potent HIV inhibitor described in
the literature, with IC50 values in the low picomolar range. The crystal structure
has been determined to be a domain-swapped homodimeric molecule [26].
GRFT has 3 mannose-binding sites in each monomeric unit, for a total of 6 highmannose binding sites. It is hypothesized that these multiple binding sites
crosslink the virus, thus accounting for GRFT’s potency. A recent report outlining
the ability of a single monomeric GRFT to bind two different nonamannoside
molecules via all 3 carbohydrate binding sites strengthens this hypothesis [27].
Because GRFT is not as well characterized as other lectins, it is
instructive to compare its features to a more well-known microbicidal candidate,
cyanovirin-N (CV-N). CV-N was originally isolated from the cyanobacterium
Nostoc elliposporum [28], and has recently been expressed in transgenic
tobacco plants [29]. Expression of CV-N in transgenic tobacco circumvented the
original problem of the bacterially-produced protein’s low yield and aggregation.
CV-N is an 11,000 Da protein with 2 glycan-binding domains. Early structural
studies indicated that the protein existed as a monomer in solution and a domainswapped dimer in crystal form [30,31]; however a recent evaluation by NMR
shows no evidence of domain-swapping, and thus the sugar-binding properties of
CV-N are due to multiple sites on the monomer [32].
Early pre-clinical efficacy studies with CV-N showed promise. CV-N
inhibited infection of human cervical explants with HIV-1 [33]. It did not induce
toxicity at the macroscopic or microscopic level in rectal epithelia of pigtailed
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macaques treated daily for 7 days with a 1% gel, nor in a single intravaginal dose
[34]. With either a 1% or 2% intrarectal treatment, 100% of macaques were
protected from intrarectal challenge with SHIV89.6P. 7 of 8 animals in each
group were protected from intravaginal challenge following treatment with 0.5%,
1% or 2% CV-N, while all animals in placebo groups were infected. However,
although no apparent toxicity to human explants or to macaques was observed,
CV-N, like many other lectins, showed pronounced mitogenic activity on
lymphocytes [35]. GRFT, on the other hand, has no mitogenic activity [24].
One possible drawback for the use of lectins such as CV-N and GRFT is
their potential, like all foreign proteins, to be immunogenic. It is not known how
an immune response to these drugs will affect their potent antiviral properties.
Thus, an extensive set of experiments must be completed to determine how
immunogenic these candidates are and how this immunogenicity may affect their
utility as microbicides.
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CHAPTER 2

MOUSE SERUM ALBUMIN IS A SENSITIVE MARKER FOR EPITHELIAL
DAMAGE IN A MURINE PRE-CLINICAL MODEL

Under normal circumstances, the human vaginal epithelium is an effective
barrier to HIV infection, with HIV transmission events estimated at 1 in every
1000 incidents [36,37]. However, upon disruption of this natural barrier the rate
of HIV-1 acquisition is drastically higher. The vaginal epithelia may be breached
by inflammation and ulceration due to other sexually transmitted infections,
disruption of the normal lactobacilli-dominated bacterial flora, or micro-trauma
caused by sexual intercourse. Any of these occurrences may lead to HIV target
cells infiltrating the site of epithelial disruption. It is therefore of utmost
importance to ensure that any microbicidal product does not result in damage or
inflammation of the vaginal epithelium.
The outcomes of several recent clinical trials have highlighted the
shortcomings of the current preclinical safety evaluations of microbicidal
products. Repeated use of the FDA-approved spermicide N-9 resulted in an
increase in HIV acquisition [2,3,4]. More recently, a CONRAD-sponsored
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efficacy trial of a cellulose-sulfate based microbicidal gel was halted as a
precaution after a non-statistically significant trend towards harm in the
experimental group was observed [3]. The preclinical safety assays used for
these products failed to predict the trial outcomes.
The current Gold Standard toxicity test for FDA approval of topicallyapplied vaginal products is the Rabbit Vaginal Irritancy (RVI) assay, first
described in 1969 [38]. This model involves daily administration of the test
product for 10 days. The endpoints are anatomical and histopathological
evaluation of the cervicovaginal mucosa. The tissue is evaluated by a
pathologist in a total of four categories: 1.) ulcerations and erosions of the
epithelial lining; 2.) thickness of the submucosal layer (edema); 3.) leukocyte
infiltration of the submucosal layer; and 4.) erythema. Each sample is scored
from 0 (normal) to 4 (severe) for each of the categories, and the total comprises
a Mean Irritation Score (MIS). One insufficiency of this assay is that it was
designed for identifying compounds that cause major irritation, and thus it lacks
the sensitivity to detect minor irritants that could still lead to enhanced
susceptibility to HIV acquisition. N-9 is perhaps the best example of this
deficiency. With an MIS <8, N-9 is identified by the RVI as a “minor” irritant
suitable for human use, however macroscopic evaluation shows evidence of
increased leukocyte infiltration, edema, and vascular congestion, as well as
disruption of the epithelial lining [39].
The RVI is increasingly viewed by those in the field as a tool for identifying
the maximum tolerated dose of a product, and newly developed assays are used
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to identify products which cause epithelial toxicity by means other than massive
irritation. These pre-clinical models employ cell and organ culture, as well as
animal models other than the RVI. Cell cultures are useful for evaluating drug
effects on cell viability and pro-inflammatory cytokine release. By monitoring
changes in the transepithelial electrical resistance (TER) of a dual chamber cell
culture system, Mesquita et al identified epithelial toxicity of cellulose sulfate (CS)
that was not predicted by the RVI or macaque challenge models [40]. The
changes in TER after N-9 or CS exposure correlated with downregulation of
junctional protein gene expression, which likely provides a route for HIV and
other viruses to cross the epithelium. Bridging the gap between cell culture and
clinical trials, tissue explants provide an invaluable tool for screening compounds
using relevant human tissues. Reconstructed human vaginal-ectocervical
epithelia are commercially available (MatTek) and can be used to evaluate the
effects of topical microbicides on tissue viability, induction of cytokines and
chemokines, and HIV susceptibility [41,42]. This model is more complex than
traditional cell culture assays, but fails to recapitulate the interaction with the
mucosal and systemic immune response of an in vivo model. A newly developed
mouse model for preclinical testing of vaginal products has recently been
described and is increasingly considered an important method for evaluating the
safety of topical microbicides. This model employs transmission of herpes
simplex virus-2 (HSV-2) as a surrogate marker for HIV transmission. HSV-2 is
an important risk factor for acquisition of HIV-1, and thus this model represents
an important advance for the microbicides field. Pathological changes in the
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mouse vaginal epithelium similar to those seen in rabbits and humans were
observed for both single [43] or repeated [44] doses of N-9. This model was also
predictive of the risk associated with cellulose sulfate-based microbicides, which
the RVI did not foresee [40].
Although advances are being made in the field of preclinical microbicide
safety, models employing HSV-2 or changes in TER require specialized training
and equipment. We hypothesized that detection of elevated levels of mouse
serum albumin (MSA) in vaginal lavage samples of mice could provide a simple
and relatively inexpensive method for screening candidate microbicides.
Movement of exogenous serum albumin across disrupted epithelium has
been used in systems other than the genital tract to show transport of
macromolecules and monitor loss of tight junctions. Fluorescently labeled bovine
serum albumin was shown to accumulate in the basolateral layer of bronchial
epithelial cells exposed to cigarette smoke in vitro [45]. Additionally, an in vivo
model of inflammatory bowel disease demonstrated that efflux of labeled BSA
into the intestinal lumen of mice following perfusion was associated with NFκBmediated internalization of tight junction proteins [46]. The work presented in this
chapter provides evidence that detection of endogenous serum albumin is a
sensitive marker of epithelial disruption in the genital tract in vivo.
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MATERIALS AND METHODS
Materials
The following over-the-counter vaginal products were purchased at Walgreen’s
pharmacy: KY Jelly® (McNeil-PPC), Conceptrol® 4% Nonoxynol-9 (Caldwell
Consumer Health), Norforms® Deodorant Suppositories (C.B. Fleet), Monistat®,
2% Miconazole Nitrate Cream (McNeil-PPC). Pharmatex®, 1.2% Benzalkonium
Chloride (BZK) (Innotech Laboratories) was purchased online from a pharmacy
in the Czech Republic. Griffithsin was formulated in Carbopol gel at 0.1% (w/v)
by Dr. Lisa Rohan’s laboratory at the Magee Women’s Research Institute at the
University of Pittsburgh School of Pharmacy. Four blinded microbicidal gels
(CO-JU10-21, -22, -23, -24) were provided by Dr. Gustavo Doncel’s laboratory at
CONRAD.

Animal Experiments
Groups of 5 BALB/c mice were injected subcutaneously with 3 mg DepoProvera (Pfizer) 3 or 4 days prior to intravaginal treatments. Mice were treated
intravaginally for 7 or 10 days with 40 μl of the products. Carbopol gel or sham
treatment was used as a negative control.
Vaginal washes were collected one day after the last treatment by
dispensing and aspirating 150 μl of 1X PBS containing protease inhibitor (GBiosciences) 10 times, and then repeating for a total collection of 300 μl lavage
fluid. The lavage samples were centrifuged at 800 rcf for 10 minutes, and the
supernatant was stored at -20oC.
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Measurement of protein concentration in lavage fluid
Protein concentration of CVL was quantified by the Bicinchoninic Assay
(BCA). BCA substrate was prepared per the manufacturer’s instructions
(Pierce). 20 µl of undiluted sample was incubated with 200 µl of BCA substrate
in a 96-well microtiter plate for 30 minutes at 37oC. Plates were read on a
BioTek Synergy HT plate reader at 562 nm.

SDS PAGE/western blot
Equal volumes of CVL samples were diluted in 2X Laemmli buffer and
separated by SDS PAGE (18% Tris-HCl gels, Bio-Rad) at 200V and stained with
SafeStain (Bio-Rad) according to the manufacturer’s instructions. For detection
by western blot, the samples in the gel were transferred to methanol-wetted
polyvinylidene difluoride (PVDF) in transfer buffer (10 mM CAPS pH 10.5, 15%
(v/v) methanol). The membrane was blocked in 5% non-fat dry milk (NFDM) in
1X PBS containing 0.05% Tween-20. Bands were detected using anti-MSA
antibody (AbCam) at 1:1000, followed by anti-rabbit IgG-HRP secondary at
1:10,000. The membrane was incubated in ECL substrate (GE Healthcare) for 5
minutes and exposed to X-ray film.

Identification of proteins of interest by Mass Spectrometry
Bands in the Conceptrol group running at ~68 kD on SDS PAGE were
analyzed by in-gel tryptic digestion and mass spectrometry. The gel was cut into
small pieces and placed in an eppendorf tube. Approximately 2 volumes of
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50mM NH4HCO3 was added and incubated at room temperature for 15 minutes.
1 gel volume of acetonitrile was added and incubated for 15 minutes. The
solvents were removed and the gel pieces were placed in a speedvac until dry.
The pieces were then swelled with 20 mM DTT in 0.1M NH4CO3 and incubated
for 45 minutes at 56oC. After removal of the DTT solution, the gel pieces were
incubated for 30 minutes in the dark with 2 volumes of 55 mM iodoacetamide in
0.1M NH4CO3. The iodoacetamide was removed and the gel washed twice with
5-10 volumes of 50 mM NH4CO3 for 15 minutes. Following a final wash of 3
volumes of NH4CO3, 4 gel volumes of acetonitrile was added and incubated for
15 minutes. The solvents were removed and the gel was dried in a speedvac.
The dried gel pieces were digested with 20 ng/ul modified trypsin (Promega) in
50 mM NH4CO3 at 37oC for 4 hours. The samples were desalted with C18
ZipTip. MS/MS data was acquired by LTQ-Orbitrap XL (Thermo Scientific). A
database search was performed using Bioworks (Thermo Scientific).

Protein quantitation by Enzyme-Linked Immunosorbent Assay (ELISA)
Samples were diluted 25-fold in 1X PBS and 100 ul was plated in
microtiter plates (Nunc Maxisorp). Mouse serum albumin (Sigma) was diluted to
1 ug/mL and serially diluted 3-fold in 1X PBS to serve as a control. Plates were
incubated overnight at 4oC. After washing in 1X PBS-T, samples were blocked in
5% non-fat dry milk in wash buffer for 2 hours at room temperature. Plates were
washed and incubated in rabbit anti-MSA at a 1:5,000 dilution in 1X PBS for 1
hour. After washing, plates were incubated with horseradish peroxidase-
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conjugated goat anti-rabbit IgG diluted 1:10,000 in 1X PBS. After a final wash,
plates were developed with SureBlue Reserve TMB substrate (KPL) and
development was stopped with addition of 1N H2SO4.
Total IgA and IgG levels were measured by double antibody sandwich
ELISA. Microtiter plates were incubated overnight with unlabeled capture
antibody (Southern Biotech). After blocking, vaginal wash samples or purified
immunoglobulin were diluted in 1X PBS and incubated for 2 hours. HRPconjugated secondary antibody against IgA or IgG was employed for detection.
Plates were developed and absorbance was measured as for the MSA ELISAs.
The pro-inflammatory cytokines IL-1β and IL-6 were quantified by double
antibody sandwich ELISA per the manufacturer’s instructions (eBiosciences).
Vaginal wash samples were diluted 5-fold in 1X PBS. All washes were
performed on an Immunowash automated plate washer (BioRad). Plates were
developed and absorbance was measured as for the MSA ELISAs.

Statistics
Graphpad Prism software version 5.04 was used for graphing results and
statistical analysis. Data were analyzed by the Kruskal-Wallis test with Dunn’s
Multiple Comparison posttest. A p-value of < 0.05 was considered significant.
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RESULTS

To identify MSA as a marker for epithelial disruption, CVL samples were
diluted 2-fold in Laemmli buffer and separated by SDS PAGE. Following
staining, a band was observed at approximately 68 kDa in all of the mice treated
with Conceptrol®, but the band was faint or not present in the mice treated with
KY Jelly® (Figure 2-1).
To positively identify the protein, the samples were analyzed by Mass
Spectrometry. The CVL samples were separated by SDS PAGE and stained.
Bands at the appropriate molecular weight were excised from the gel and an ingel tryptic digest was performed. The digested protein was run on a LTQOrbitrap. A database search was performed using Bioworks Software, and the
protein was identified as mouse serum albumin (Figure 2-2).
To evaluate the effect of over the counter (OTC) vaginal products, mice
were treated daily for 10 days to determine if any commercially available
products resulted in increased levels of MSA, IgA, IgG, IL-1β or IL-6 in the CVL.
All commercially-available products were purchased at Walgreens, except for
Pharmatex®, which was purchased online from a pharmacy in the Czech
Republic.
CVL samples were analyzed for MSA levels by western blot and ELISA
(Figure 2-3). By western blot, the sham treatment and Norforms had the lowest
amount of MSA in the CVL. The CVL from mice treated with Pharmatex® clearly
contained the highest level of MSA. The western blot results were in agreement
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with the levels of MSA quantified by ELISA. By the Kruskal-Wallis test, mice
treated with either Conceptrol® and Pharmatex® had significantly more MSA in
the CVL than the mice in the sham treatment group (p = 0.001).
Total IgA and IgG levels were quantified by ELISA (Figure 2-4). Overall
levels of IgA were higher and more variable than for IgG. None of the test
groups had a statistically significant increase in IgA levels over untreated mice (p
= 0.1445). For total IgG, only mice treated with BZK had a markedly higher
concentration of this immunoglobulin in their CVL than any other mice (p =
0.0013). Neither IgA nor IgG predicted damage by N-9 treatment.
The pro-inflammatory cytokines IL-1B and IL-6 were also analyzed in the
CVL of mice treated with various vaginal products (Figure 2-5). IL-1β levels
were low overall, with KY Jelly producing the highest average concentration.
None of the treatment groups had a statistically significant increase of IL-1β over
the untreated group (p = 0.3045). IL-6 concentrations were highest in the N-9
treated animals, followed by BZK (p = 0.0241).
To determine if detection of MSA could predict damage resulting from
formulated microbicidal gels such as Cellulose Sulfate, a panel of four gels was
obtained from CONRAD. Mice were treated daily for 10 days. As in the previous
experiment, CVL samples were analyzed by western blot and ELISA (Figure 26).
As for the experiment employing OTC products, the mice in this
experiment treated with Pharmatex® clearly had the most MSA in the CVL by
immunoblot analysis. One mouse in the KY Jelly® group and two mice in the
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CO-JU10-24 groups had comparable levels of MSA to the mice treated with
Pharmatex®. The mice in the other three treatment groups (CO-JU10-21, -22,
and -23) exhibited similar MSA levels to sham-treated mice. The ELISA results
for the blinded groups were not in complete agreement with the western blot
data. By ELISA, the Pharmatex®-treated mice again contained a significantly
increased concentration of MSA in the CVL as compared to the sham treatment
group (p = 0.0058). However, in contrast to the western blots, the median
concentration of MSA in the CO-JU10-24 group was much lower than for COJU10-23 (0.446 µg/mL vs. 3.207 µg/mL).
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Figure 2-1. SDS PAGE of cervicovaginal lavage samples. Mice were treated
daily for 10 days with KY Jelly® or Conceptrol® containing nonoxynol-9 (N-9).
CVL samples were boiled with 2X loading dye and separated on an 18% gel.
Kaleidoscope molecular weight marker was used to approximate protein
molecular weights. Bands were visualized by staining in SafeStain. The arrow
indicates the band corresponding to mouse serum albumin (MSA), which is
approximately 68 kDa.
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Figure 2-2. Identification of mouse serum albumin by in gel tryptic digest
and mass spectrometry. Digested protein was analyzed on an LTQ-Orbitrap
Mass Spectrometer and protein fragments were identified as MSA following a
database search by BioWorks Software (Thermo Scientific).
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A.

B.

Figure 2-3. MSA concentrations in the CVL increase after exposure of mice
to known epithelial disrupters. Mice were treated daily for 10 days with
various OTC vaginal products or GRFT formulated in carbopol gel. MSA
concentrations in the CVL were evaluated by immunoblot (A.) and ELISA (B.).
Levels of MSA were significantly increased in mice treated with N-9 or BZK,
compared with untreated mice. Bars indicate mean MSA concentration.
Asterisks indicate p < 0.05 (*) or p < 0.01 (**), Dunn’s Multiple Comparison
Posttest.
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A.

B.

Figure 2-4. The effect of OTC vaginal products on immunoglobulin
concentrations in the CVL. Mice were treated daily for 10 days with various
OTC vaginal products or GRFT formulated in carbopol gel. Total IgA and IgG
concentrations in the CVL were evaluated by ELISA. Levels of IgA were not
significantly different from untreated animals in any of the groups. IgG levels
were significantly increased in mice treated with BZK, compared with untreated
mice. Bars indicate mean immunoglobulin concentration. Asterisks indicate p <
0.01, Dunn’s Multiple Comparison Posttest.
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B.

B.

Figure 2-5. Concentrations of IL-6, but not IL-1β, are predictive of epithelial
damage. Mice were treated daily for 10 days with various OTC vaginal products
or GRFT formulated in carbopol gel. IL-1β and IL-6 concentrations in the CVL
were evaluated by ELISA. Levels of IL-1β were not significantly different from
untreated animals in any of the groups. IL-6 levels were significantly increased in
mice treated with BZK and N-9, compared with untreated mice. Bars indicate
mean cytokine concentration. Asterisks indicate p < 0.05 (*) or p < 0.01 (**),
Dunn’s Multiple Comparison Posttest.
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Figure 2-6. MSA levels in CVL are predictive of damage by BZK. Western
blots (A.) and ELISA (B.) of cervicovaginal lavage samples from mice treated
with either KYJelly®, BZK, or a blinded panel of microbicides.
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DISCUSSION

There is currently no effective vaccine against HIV, and thus other
preventative measures must be used to thwart infection. Sexual transmission of
the virus is the primary way in which it is spread, and microbicides which can be
used prior to sexual intercourse may be an important tool for prevention,
especially for women who cannot negotiate for condom use. The microbicides
field has faced some setbacks, however, stemming from a number of products
which failed to prevent the spread of HIV, or showed a trend towards harm, in
several clinical trials. These failures were due at least in part to the lack of
predictive preclinical safety data. In vitro assays are useful to a degree but lack
the complexity of an intact reproductive system. A simple in vivo screening
method for epithelial damage that could be employed in concert with other
preclinical assays would be especially useful for the microbicides field.
The over-the-counter spermicide nonoxynol-9 (N-9) was tested
extensively in clinical trials as a microbicidal candidate. Unfortunately it was not
effective in preventing HIV-1 and other sexually transmitted infections at low
frequency of use. With more frequent use (>3.5 applicators per day), a
statistically significant increase in the rate of HIV-1 seroconversion was
observed. Additionally, N-9 use resulted in the increased acquisition of multiple
types of human papillomavirus (HPV) [47]. These resulting HIV and HPV
infections were thought to be due to N-9 induced epithelial disruption. Mesquita
et al provided further evidence for this by showing that both N-9 and cellulose
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sulfate induce a reduction in the transepithelial electrical resistance and
downregulation of tight junctional proteins [40].
MSA is the most abundant protein in serum. Its presence in vaginal
washes at elevated concentrations may indicate damage to the vaginal
epithelium. In the initial experiment, mouse serum albumin was identified by ingel tryptic digest and mass spectrometry as the most prevalent protein in the
cervico-vaginal lavage samples from mice treated with N-9. Faint bands at 68
kDa were observed in the mice treated with KY Jelly® as well, however they were
not nearly as prominent as the bands in the N-9 treated group. It’s likely that
MSA leaked into the vaginal lumen because of the loss of tight junctions between
the epithelial cells in the N-9 treated mice.
In the following experiment, mice were treated with a variety of over-thecounter vaginal products and formulated GRFT. The CVL samples were
analyzed by western blot and ELISA, and the amount of MSA was compared with
the untreated mice. As expected, the CVL of N-9 treated mice had a high
concentration of MSA. The mice treated with Benzalkonium Chloride also had
elevated levels of MSA in the CVL. This is unsurprising because BZK is a known
epithelial disrupter [48,49]. Spermicides containing BZK are not sold in the
United States due to the risks associated with its use, but are still available in
other countries. The other products tested – KY Jelly®, Norforms® deodorant
suppositories, Monistat® anti-fungal cream, and formulated GRFT – had levels of
MSA that were not significantly different than the untreated mice. The Norformtreated mice showed a trend toward lower levels of MSA than the untreated
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mice. This may be due to the consistency of the product. To make the Norform
product, which is supplied as a solid suppository, amenable to pipetting the
product was melted at 37oC then mixed with 3% carboxymethylcellulose (CMC)
until it no longer solidified at room temperature. The resulting admixture was
thick and viscous, possibly producing a dense barrier along the vaginal
epithelium which resulted in reduced transudation of proteins across the vaginal
epithelium.
Levels of total IgA and IgG were evaluated in these mice as well, because
these immunoglobulins are also abundant in serum and an increased
concentration in the CVL may provide an additional marker for epithelial damage.
Both immunoglobulins were elevated in the CVL of mice treated with BZK, but
not for N-9. This indicates that presence of high concentrations of IgA and IgG
are predictive of gross damage to the epithelium, but fails to predict minor
irritants which still impact HIV acquisition.
Local production of the pro-inflammatory cytokines IL-1β and IL-6 have
been associated with decreased safety profile of microbicides [50,51]. In this
study, levels of IL-1β were similar among all treatment groups. IL-6 levels were
significantly different from untreated mice in the N-9 and BZK groups.
Surprisingly, the N-9 treated mice had higher levels of IL-6 in the CVL than the
more damaging BZK.
In the final experiment, mice were treated with KY Jelly, BZK, or one of
four blinded microbicidal products provided by CONRAD. Levels of MSA were
analyzed by ELISA and western blot, and these were compared to levels for
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sham-treated mice. Again, the concentration of MSA in the CVL was highest for
BZK-treated mice. By ELISA, the group treated with CO-JU10-23 had the highest
overall levels of MSA of any of the groups treated with blinded microbicides, but it
was not significantly different from the sham-treated mice. The ELISA results
were similar to the data obtained from immunoblotting. BZK-treated mice
showed the highest levels of MSA by western blot, followed by mice treated with
either CO-JU10-23 or CO-JU10-24. These microbicides have not yet been unblinded to us by CONRAD, but it is likely that one of these gels may be Cellulose
Sulfate, which is known to perturb the vaginal epithelium.
One limitation with analyzing protein content and concentration in the CVL
is that there is no appropriate “loading control” to which data can be normalized.
Unlike analyzing cell lysates, in which data can be standardized to the number of
cells plated and the housekeeping protein concentrations expected with that
number of cells, the vaginal vault is an open system into which serum proteins
can enter. Because GRFT is a protein-based drug, and because many markers
for damage are proteins, it is inappropriate to normalize data to total protein
concentration. Thus all analyses must be done based on the assumption that the
volume of CVL obtained is the same for each mouse, and that the samples are
representative of the proteins present in the vaginal canal along the epithelial
surface. A solution to this problem remains an issue for the microbicides field.
In addition to identifying compounds which damage the epithelium of mice,
increased levels of serum albumin may be useful for predicting damage in
humans. The presence of certain sexually transmitted infections or
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microtraumas which disrupt epithelial integrity are associated with an increased
risk of HIV acquisition. Measuring levels of serum albumin in women may
provide a facile method of identifying women who are at higher risk of infection,
especially in resource-limited settings where colposcopy is not always available.
Continued research into this area is needed.
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CHAPTER 3

IMMUNOGENICITY OF VAGINALLY- AND SYSTEMICALLYADMINISTERED GRFT

Currently there is no vaccine to prevent the spread of HIV-1. In the
absence of a vaccine, there has been increasing interest in topical microbicides
which can impede the spread of HIV-1 and other sexually transmitted infections
(STIs). Ideally a microbicide that is used for prevention of STIs should not
activate the innate or adaptive immune response. However GRFT, like all
protein-based drugs, may be immunogenic, and it is important to fully understand
the consequences of any immune response in terms of safety and drug efficacy.
The female genital tract is an established site of induction of adaptive
immune responses [52]. Systemic and local immune responses to Cholera Toxin
B subunit (CTB) were evaluated in women following administration via the oral,
rectal, or vaginal route [53]. Vaginal IgA and IgG was highest in vaginal
secretions following vaginal administration, and all routes of administration
resulted in higher concentrations of CTB-specific systemic IgA and IgG than in
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pre-immune serum. However, it should be noted that there was great variation in
the magnitude of antibody response in vaginal secretions among the women,
possibly due to administration of the antigen at different phases of the menstrual
cycle [54].
In laboratory rodents, immune responses vary throughout the estrous
cycle. During diestrus, the immune response is dampened in the upper genital
tract and is enhanced in the lower tract, presumably to facilitate fertilization and
prevent infection in the pregnant doe [55,56]. Dendritic cells, MHC class II+ cells,
and antigen-presenting cells are present in increased numbers and the vaginal
epithelium is thinned during the progesterone-dominated diestrus phase, which
may enhance an immune response to vaginally-applied products [55,56].
Injection with depot medroxyprogesterone (Depo-Provera) mimics this effect.
The work presented in this chapter will detail the adaptive immune response to
intravaginally applied GRFT in Depo-Provera treated mice.
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MATERIALS AND METHODS
Animal Experiments
Six to eight week old BALB/c (Jackson Labs) or SKH1-E (Charles River) hairless
mice were injected subcutaneously with 3 mg Depo-Provera (Pfizer) 3 or 4 days
prior to each experiment. Animals were euthanized by CO2 asphyxiation and
death confirmed by cervical dislocation.
To evaluate the effect of route of administration on local and systemic
antibody levels, animals were treated weekly with either GRFT or GRFTlec-. 1.2
µg of each protein were diluted in 1X PBS and injected subcutaneously (s.c.), or
12 µg of GRFT or GRFTlec- mixed in carbopol gel and administered intravaginally
(ivag) using a positive-displacement pipette. A total of 6 treatments were
administered. Samples were collected one week after the final treatment.
To compare the antibody response to two doses of two lectins, mice were
administered six weekly intravaginal doses of either 1.2 or 12 µg of GRFT,
GRFTlec-, or cyanovirin-N (CV-N) mixed with KY Jelly.

Sample Collection
CVL: Cervico-vaginal lavage (CVL) samples were collected by dispensing and
aspirating 150 μl of 1X PBS containing protease inhibitor 10 times, and then
repeating for a total of 300 µl CVL. The lavage samples were centrifuged at 800
rcf for 10 minutes, and the supernatant was stored at -80oC.
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Serum: Terminal bleeds were collected via cardiac puncture after mice were
euthanized by CO2 asphyxiation and cervical dislocation. Blood collected in
serum separator tubes clotted for 30 minutes at room temperature, then was
centrifuged for 5 minutes at 6000 rcf. Serum was stored at -80oC.

Splenocytes: Spleens were removed and placed in RPMI 1640 containing 2%
Fetal Bovine Serum (FBS). The tissue was crushed on metal mesh with forceps,
and the cell suspension was centrifuged at 450 x g for 5 minutes. The cells were
resuspended in ACK lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM
Na2EDTA) and incubated for several minutes. Additional medium was added to
the suspension and centrifuged again. The resulting cell pellet was resuspended
in RPMI 1640 containing 10% FBS and filtered through a 0.2 micron filter.

ELISA
Plates were coated with 0.25 µg/ml gp120. Wells were blocked with 5%
(w/v) non-fat dry milk in 1X PBS-T. Following blocking, 2 µg/mL GRFT or CV-N
in 1X PBS was added and incubated for 1 hour. Test serum or CVL was diluted
in 1X PBS and incubated for 1 hour at RT. Pre-immune serum or CVL served as
the background control. Goat anti-Mouse IgG-HRP or IgA-HRP was added. The
plate was developed with KPL SureBlue TMB Microwell Peroxidase Substrate,
and the reaction was stopped with addition of 1N H2SO4. The plate was read at
an OD of 450nm. Antibody titers are represented as the reciprocal of the dilution
that gave a reading of twice background.

36

ELISpot
IL-4 and INFγ capture antibodies were diluted in 1X PBS and coated on
ELISpot plates (Millipore) overnight at 4oC per the manufacturer’s instructions
(eBiosciences). Wells coated with PBS only were used as background controls.
Plates were washed twice with 1X PBS and blocked for 1 hour at room
temperature with RPMI 1640 containing 10% FBS. After washing the plates 3
times in 1X PBS, GRFT or CV-N was added at 10 µg/mL in RPMI 1640/10%
FBS. Five-fold serial dilutions, starting at 107 cells per mL, were added in
quadruplet, so that 3 wells at each dilution contained capture antibody and 1 well
served as a background control. Cells and stimulants were co-incubated for 24
hours at 37oC. Plates were washed and biotinylated detection antibody was
added and incubated for 2 hours. Plates were washed extensively in PBS-T,
then Avidin-HRP was added and incubated for 45 minutes. Following extensive
washings with both PBS-T and PBS, the plates were developed with freshly
prepared AEC substrate for 60 minutes. The reaction was stopped with water
and the plates allowed to dry. Plates were imaged on an Immunospot (Cellular
Technology, Ltd.) with Immuno Capture 6.3 software, and spots were counted
using ImmunoSpot 5.0 Pro DC.

Positron Emission Tomography
2.5 nmol DOTA-GRFT was mixed with 64Cu in ammonium acetate buffer
(100 µL, pH 8), and was incubated at room temperature for 15 minutes. The
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labeled mixture was passed through a NAP-5 column, and the labeled protein
was eluted with PBS. The labeling yield was in the range of 80-90%. The
radiochemical purity was greater than 99% based on analytical HPLC analysis.
The labeled protein was mixed with carbopol gel and administered to SKH1-E
mice with a positive displacement pipette. The mice were anesthetized with
isofluorane, and the animals were imaged with a MicroPET rodent R4 scanner
from Siemens. Images were acquired with ASIPro and Analyze imaging software.

Statistics
Graphpad Prism software version 5.04 was used for graphing results and
statistical analysis. Data were analyzed by the Mann-Whitney test. A p-value of
<0.05 was considered significant.
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RESULTS

Weekly doses of GRFT or GRFTlec- were administered either
subcutaneously or intravaginally for 6 weeks. Systemic and local antibody
responses were analyzed by gp120 capture ELISA. Intravaginal administration
of GRFT elicited significantly higher serum antibody titers than subcutaneous
administration (p = 0.0350) (Figure 3-1). For GRFTlec-, the trend was the same
as for GRFT, but the difference was not statistically significant (p = 0.2059).
GRFT-specific IgA levels in the CVL were evaluated for the same mice
(Figure 3-2). Surprisingly, the mean concentration of GRFT-specific IgA was
higher for the subcutaneously-treated mice than for those treated intravaginally,
however this difference was not statistically significant (p = 0.5476). Mice treated
with GRFTlec- had lower overall IgA antibody levels in the CVL, and there was no
significant difference between the routes of administration.
To monitor the distribution of GRFT in the genital tract following
intravaginal administration, GRFT was labeled with Cu-64 and mice were
subjected to positron emission tomography (PET). Scans were taken at 1, 2, 7
and 31 hours after administration of the gel (Figure 3-3). GRFT was present in
the vagina at all time-points. Surprisingly, labeled GRFT had traversed the cervix
and entered the uterus within an hour. By the last time-point, labeled GRFT was
observed in the peritoneum.

39

To further evaluate mucosal administration of GRFT, female BALB/c mice
were administered six weekly intravaginal doses of either 1.2 or 12 μg of GRFT,
GRFTlec-, or cyanovirin-N (CV-N), another lectin that is also being developed as a
potential microbicide. Antibody titers were measured in serum and CVL in a
gp120-binding ELISA (Figure 3-4). Serum antibody titers were relatively high for
all three groups treated with the high dose (12 μg of protein), but only animals
treated with the low dose of GRFT (1.2 μg) also had high serum antibody titers.
The difference between low and high dose was only statistically significant for
mice treated with GRFTlec- (p = 0.0254). Mucosal IgA levels were fairly low,
however mice treated with 12 μg of GRFT had higher CVL IgA levels than other
mice. The difference between low and high doses of GRFT was not statistically
significant. Likewise, increasing the dose of the microbicide did not result in
statistically higher levels of IgG in the CVL for any of the groups.
To measure T-cell responses to GRFT or CV-N, splenocytes from treated
animals were evaluated for cytokine release by ELISpot after stimulation with
GRFT or CV-N (Figure 3-5). Overall numbers for both IL-4 and INFγ were low.
Both low and high dose treatments of CV-N resulted in 2- to 4-fold higher number
of interferon gamma-secreting cells than seen in mice treated with GRFT or
GRFTlec-. Numbers of IL-4-secreting splenocytes elicited by treatment with the
microbicides were dose-dependent, with IL-4 secreting cells only evident in the
animals treated with the higher dose.
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Figure 3-1. Intravaginal administration of GRFT, but not GRFTlec-, induces
higher titers of serum IgG antibodies than subcutaneous administration.
Mice were treated intravaginally or subcutaneously with either GRFT or GRFTlecweekly for 6 weeks. Anti-GRFT IgG titers in the serum were determined by
gp120 capture ELISA. Bars indicate mean endpoint titers. Asterisk indicates p =
0.0350, Mann-Whitney test.
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Figure 3-2. GRFT-specific IgA concentrations in the cervico-vaginal
lavages are low following either subcutaneous or intravaginal
administration of GRFT or GRFTlec-. Mice were treated intravaginally or
subcutaneously with either GRFT or GRFTlec- weekly for 6 weeks. Anti-GRFT
IgA titers in the CVL were determined by gp120 capture ELISA. Bars indicate
mean endpoint titers.
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Figure 3-3. Intravaginally administered Cu-64 labeled GRFT travels
throughout the genital tract. Cu-64 labeled protein was mixed with carbopol
gel and administered to SKH1-E hairless mice intravaginally with a positive
displacement pipette. Mice were imaged by positron emission tomography (PET)
at 1, 2 7, and 31 hours after administration.
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A.

B.

C.

Figure 3-4. Antigen-specific levels of serum IgG (A.), or mucosal IgA (B.)
and mucosal IgG (C.) in cervicovaginal lavages. Female BALB/c mice were
administered six weekly intravaginal doses of either 1.2 or 12 μg of GRFT,
GRFTlec-, or cyanovirin-N (CV-N). Antibody titers were measured in serum and
CVL in a gp120-binding ELISA.
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Figure 3-5. T-cell responses to GRFT or CV-N following stimulation of
splenocytes from treated animals. To evaluate the T-cell responses, 1 week
after the final dose splenocytes from the immunized mice were stimulated with
antigen for 2 days, and the number of cells secreting IL-4 and INFγ were
counted. Bars indicate mean + SEM.
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DISCUSSION

GRFT is a promising candidate as a vaginal microbicide. To date, its
safety profile indicates that it is not mitogenic, does not cause inflammatory
cytokine release, and does not decrease cell viability [24,57]. However, like all
lectins it has the capacity to be immunogenic. To understand GRFT’s ability to
raise an immune response, mice were exposed to GRFT without adjuvant, either
via the subcutaneous or mucosal (intravaginal) route.
A subcutaneous dose of 1.2 ug of GRFT had been used previously [58]
and because many mucosal antigens are taken up at very low levels [52], we
selected a 10-fold higher dose for mucosal administration. Repeated intravaginal
exposure of mice to either GRFT or GRFTlec- did not produce high titers of IgA or
IgG antibodies to GRFT in the vaginal vault. In fact, two of the mice injected
subcutaneously with GRFT had the highest titers of IgA antibodies at the
mucosal surface. Surprisingly, intravaginal administration of GRFT resulted in
higher titers of serum IgG antibodies than subcutaneous administration did.
From data collected using positron emission tomography, we found that GRFT
travels readily through the female reproductive tract and into the peritoneum.
This may explain why intravaginal administration of GRFT results in high titers of
systemic anti-GRFT antibodies.
To further evaluate mucosal administration of GRFT, female BALB/c mice
were administered six weekly intravaginal doses of either 1.2 or 12 µg of GRFT,
GRFTlec-, or cyanovirin-N (CV-N). Serum antibody titers were relatively high for
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all three groups treated with the high dose (12 µg of protein), but only animals
treated with the low dose of GRFT (1.2 µg) also had similarly high serum
antibody titers. The reason for low doses of GRFT eliciting high systemic
antibody titers is unclear. GRFT, but not GRFTlec-, binds the vaginal epithelium
[57]. This binding may enhance the retention time of lectin-based microbicides in
vivo, thus increasing the amount of drug that reaches the systemic immune
system.
Induction of anti-GRFT antibodies could impair its utility as a microbicide
by interfering with its ability to bind to glycoproteins. This could occur by an
antibody that binds directly to the carbohydrate-binding moieties on GRFT, or
may be the result of steric hindrance. Further testing will need to be completed to
evaluate what, if any, effect these specific antibodies have on GRFT’s antiviral
activity.
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CHAPTER 4

CONCLUSIONS AND FUTURE DIRECTIONS

Our GRFT-based gel product presents an appealing innovation in the
microbicide field. Because it is a small protein, and not orally bioavailable, it is
unlikely that GRFT will be developed as part of the normal antiretroviral treatment
regimen, making it available for prophylaxis without compromising populationlevel antiretroviral efficacy through promoting drug resistance. This is an
important differentiating factor for GRFT and other protein- and peptide-based
microbicides since there are serious concerns about whether antiretrovirals that
are used in treatment regimens are appropriate for use in prophylaxis, since the
risk of resistance due to suboptimal viral suppression compromises the
therapeutic use of not only the specific drug, but also members of the same class
of drug [59,60]. Recently, Schader et al. demonstrated that for the leading nonnucleoside reverse transcriptase inhibitor (NNRTI) microbicide candidate,
Dapivirine (DAP), evolution of viral resistance associated with incomplete viral
replication suppression resulted in cross-resistance to Nevirapine (NVP), a
related NNRTI that is vitally important in HIV therapy and perinatal HIV
transmission prophylaxis protocols in sub-Saharan Africa [61]. We have
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demonstrated that GRFT exhibits significant antiviral synergism with leading
small molecule ARV Tenofovir (TFV), Maraviroc, Enfuvirtide [62], and Raltegravir
(presented at CROI, 2012).
Amongst all protein- and peptide-based microbicide candidates, GRFT
has many outstanding advantages. Foremost is its mid-picomolar potency
against a broad range of HIV-1 strains, its activity against HSV-2 [63,64], and
against Heptatitis C virus (HCV) [65]. Although HCV is not primarily a sexually
transmitted pathogen, there is increasing evidence that it may be sexually
transmitted in some HIV positive populations. GRFT has remarkable
environmental stability, with a thermal melting temperature in excess of 78°C,
and strong resistance to digestion by human and bacterial proteases [24,66,67].
Our GRFT carbopol gel formulation shows good API release kinetics and product
stability. In preclinical tests, the API and gel product have an excellent safety
profile [24,57].
Perhaps the most concerning theoretical safety issue for protein- and
peptide-based microbicides is the potential for immunotoxicity. Xenogenic
proteins, such as GRFT, may induce inflammatory immune responses.
Moreover, there is a risk that on repeated use, anti-drug immunoglobulins could
lead to neutralization of the lectin’s activity. These risks have generally not been
addressed by other groups who propose lectins as microbicides. GRFT is not
mitogenic, does not activate T-cells, and induces very little alteration in secretion
of inflammatory cytokines in treated PBMC from multiple human donors [24,57].
Similarly, we have not observed production of inflammatory cytokines in mucosal
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secretions of rabbits treated with unformulated API [24] and mice treated with
GRFT gel formulations, but we have confirmed that GRFT and CV-N both induce
systemic antibody responses and very low titers of binding mucosal antibodies
after vaginal administration to Depo-Provera treated mice, which have
substantially thinned vaginal mucosa after hormonal treatment.
It is important to note that all of the in vitro experiments in the previous
chapters were performed in the context of Depo-Provera (medroxyprogesterone
acetate) pre-treatment. This is done primarily to thin the vaginal epithelium and
increase susceptibility to drug treatment. However, it also reflects the fact that
Depo-Provera and other injectable progesterone drugs are a major form of
contraceptives used by women worldwide, especially in developing countries
[68,69]. The use of hormonal contraceptives by women at high risk of HIV
acquisition is somewhat controversial. Hormonal contraception is vitally
important for women to have control over their fertility. Some studies have
associated the use of hormonal contraceptives with an increased risk in HIV
transmission [70,71,72], while others have not [72,73]. This uncertainty
prompted the World Health Organization to review the literature and consider
whether the previous guideline Medical eligibility criteria for contraceptive use,
Fourth edition 2009 should be altered in light of these published studies [74].
Ultimately the review panel deemed injectable hormonal contraceptives safe,
with a strong clarification as to the potential risks for women at high risk of HIV
infection.
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Future work for this project includes further evaluation of GRFT’s
acceptability as a protein based microbicide. We will assess its ability to alter the
innate immune response within the vaginal mucosa by measuring the number of
HIV target cells after single or repeated doses of formulated gel. We will
determine the consequences of anti-GRFT antibodies following repeated
mucosal administration, assaying reduction of HIV gp120 binding associated with
GRFT antibodies and neutralization of GRFT’s HIV pseudovirus neutralization
activity. We will also evaluate the impact of an antibody response to GRFT on its
ability to protect mice from HSV-2 challenge, as well as the impact of an immune
response to GRFT on gene and protein expression of key factors involved in
HSV-2 infection. These future studies will provide a comprehensive overview of
the innate and adaptive immune responses to GRFT, as well as any resulting
consequences of that response.
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